Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

In clinical trials recombinant-modified vaccinia virus Ankara expressing the Mycobacterium tuberculosis antigen 85A (MVA85A) induces approximately 10 times more effector T cells than any other recombinant MVA vaccine. We have found that in BCG primed subjects MVA85A vaccination reduces transforming growth factor beta 1 (TGF-beta1) mRNA in peripheral blood lymphocytes and reduces TGF-beta1 protein in the serum, but increases IFN-gamma ELISPOT responses to the recall antigen SK/SD. TGF-beta1 is essential for the generation of regulatory T cells and we see a correlation across vaccinees between CD4+CD25hiFoxP3+ cells and TGF-beta1 serum levels. This apparent ability to counteract regulatory T cell effects suggests a potential use of MVA85A as an adjuvant for less immunogenic vaccines.

Original publication

DOI

10.1016/j.vaccine.2008.07.040

Type

Journal article

Journal

Vaccine

Publication Date

26/09/2008

Volume

26

Pages

5269 - 5275

Keywords

Acyltransferases, Adolescent, Adult, Antigens, Bacterial, BCG Vaccine, Down-Regulation, Female, Forkhead Transcription Factors, Humans, Interferon-gamma, Leukocytes, Mononuclear, Male, Middle Aged, Mycobacterium tuberculosis, Transforming Growth Factor beta1, Tuberculosis Vaccines